Stock JSPR JASPER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq
Other stock markets
 21:00:00 16/05/2024 BST 		5-day change 1st Jan Change
22.84 USD +5.76% Intraday chart for Jasper Therapeutics, Inc. +6.65% +189.54%
05-13 Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4 MT
05-07 Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
AQ
Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4
MT
Jasper Therapeutics : Corporate Presentation May 2024
PU
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
AQ
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
AQ
Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
Certain Common Stock of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target
MT
Jasper Therapeutics : Corporate Presentation April 2024
PU
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65
MT
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset
MT
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
AQ
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
AQ
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
CI
TD Cowen Initiates Jasper Therapeutics With Outperform Rating
MT
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
AQ
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia
CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JSPR Stock
  4. News Jasper Therapeutics, Inc.